Levomepromazine and Weaning from Sedation in Traumatic Brain Injured Patients

Benaddi Loubna; MA. Fehdi; MR. ElAbassi; G. Berdai; A. Mrani Alaoui; A. Nsiri; R. AlHarrar

doi:10.36948/ijfmr.2023.v05i05.6625

Levomepromazine and Weaning from Sedation in Traumatic Brain Injured Patients

Author(s)	Benaddi Loubna, MA. Fehdi, MR. ElAbassi, G. Berdai, A. Mrani Alaoui, A. Nsiri, R. AlHarrar
Country	Morocco
Abstract	Background: Sedation is a key for the management of patients with traumatic brain injuries. However, in some of the brain injured patients, weaning from sedation is a real challenge. In this work, we aim to evaluate the use of Levomepromazine as a safe strategy for weaning from sedation in mechanically ventilated brain injured patients. Patients and Method: This is a prospective randomized controlled monocentric study carried out on patients admitted to the surgical ICU of the university hospital Ibn Rochd of Casablanca, between January 2022 and April 2022. The study included all mechanically ventilated patients over 18 years old admitted for traumatic brain injury. The patients were divided in two groups. The primary endpoint assessed was the need to resume sedation. Results: In our study, the average age was 30 years ± 10.9. 97% were men. Resumption of sedation was 73.3% in the control group compared to only 37,5% in the group who took levomepromazine. Agitation was significantly lower in the levomepromazine group 18.7% compared to 73,3% in the control group. The reasons of re-sedation in both groups were accidental extubation due to the agitation of the patient and also patient-ventilator asynchrony. The length of stay was reduced in the control group with 18,4 days versus 28,7 days in the levomepromazine group. Concerning the impact on ICU deaths, there was no significant difference. Conclusion: Levomepromazine has been shown through this work to reduce agitation in traumatic brain injured patients. ICU Death may not be influenced by the use of this molecule but it would reduce the need for prolonged or re-sedation.
Keywords	Levomepromazine, traumatic brain injury, Sedation, Weaning, Agitation, Re-sedation
Field	Medical / Pharmacy
Published In	Volume 5, Issue 5, September-October 2023
Published On	2023-09-28
Cite This	Levomepromazine and Weaning from Sedation in Traumatic Brain Injured Patients - Benaddi Loubna, MA. Fehdi, MR. ElAbassi, G. Berdai, A. Mrani Alaoui, A. Nsiri, R. AlHarrar - IJFMR Volume 5, Issue 5, September-October 2023. DOI 10.36948/ijfmr.2023.v05i05.6625
DOI	https://doi.org/10.36948/ijfmr.2023.v05i05.6625
Short DOI	https://doi.org/gstdc4

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 4 Cover Page Vol 6 Isu 3 Cover Page Vol 6 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Levomepromazine and Weaning from Sedation in Traumatic Brain Injured Patients

Share this